Sorrel’s technological flexibility, coupled by our total market approach, strike the perfect balance between what is best for the patients and what is optimal for pharma companies
Based on our high-end patents and groundbreaking design, Sorrel is suited for multiple configurations, molecules, and indications. This next-generation digitally integrated platform is intended for subcutaneous delivery of injectable drugs, biologics, and biosimilars.
Sorrel’s on-body systems are hassle-free and simple to use, to generate improved outcomes just as the patient wants and exactly as the pharma company directs. Our technology delivers more, your way.
Our innovation is specifically designed to fit into the changing regulatory, industrial, and data privacy landscape. This opens up new therapy options that transform the way healthcare is delivered; ensuring an improved patient self-administration experience with a true platform-solution for Sorrel’s partnering companies.

- Electro-mechanical pumping mechanism
- Reliable and proven technologies
- Accurate and controlled dose
- Volume per step 0.6 µL
- ±5% accuracy
- Gentle handling of the molecule delivered, by avoiding pressure and shear forces built on liquid
- Decoupling the pumping mechanism from the primary container, allows for:
- Different container types
- Different volumes
- Different materials and manufacturers
- All based on the same technology, with minimal changes to device
- Enables a true platform solution
Multiple sensors in place to ensure a confident and successful self-administration experience
- Air detection
- Occlusion
- Primary container in place
- On-body detection
- Needle position
- Internal system checks
Recognizing the importance of a pre-filled and pre-loaded solution
- Enhances user experience
- Increases patient adherence to therapy
- Ultimate and innovative solution in place utilizing a UV-C LED
- Enabling full sterility of fluid path
- Utilizing standard primary containers with no complex fluid lines and established filling processes, no disruption
- Simplifies product design and manufacturing
- Bluetooth® low energy and NFC enabled in the Sorrel devices
- Team experienced with connectivity, cybersecurity and HIPAA regulations from marketed infusion pumps
- Dedicated application in development for clinical trial use
- Displaying treatment summary to user and sharing event logs with healthcare provider or clinical trials investigator
Device Specifications
Primary Container
Flexibility in volume, dimensions, and material of primary container. Pre-loaded, loaded by user, or filled at point of care per partner choice.
Current configurations in development:
- 1 mL, with internal drug reservoir, filled at point of care
- 3 mL, 5 mL, 10 mL , 20 mL and 25 mL, with a pre-filled and pre-loaded cartridge or vial
Flow Rate
Up to 3 mL/min, pre-programmable and customizable
Needle System
Concealed needle, with automated insertion and retraction
Connectivity
Bluetooth® and NFC enabled
Accuracy
±5%
The Sorrel products: Limited by Unites States law to investigational use